|
Loading...
Loading...
US Pharm. 2011;36(4):8.
Gaithersburg, MD—The FDA has approved Benlysta (belimumab) for the treatment of systemic lupus erythematosus. It is the first new drug indicated for the autoimmune disorder since corticosteroids and Plaquenil (hydroxychloroquine) were approved in 1955. Two clinical studies involving 1,684 patients with lupus demonstrated the safety and effectiveness of Benlysta, which is delivered via intravenous transfusion and targets B-lymphocyte stimulator (BLyS) protein. Patients treated with Benlysta and standard therapies experienced less disease activity and had a reduced likelihood of severe symptom flares than those who received a placebo and standard therapies.
To comment on this article, contact
rdavidson@uspharmacist.com.
|
Loading...
Loading...
|
|
U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date,
authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings,
including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations,
long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students,
other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn
Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE)
as a provider of continuing pharmacy education.
Copyright © 2000 - 2013 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.
|